Incident adverse events following therapy for acute promyelocytic leukemia

Peter Geon Kim(Massachusetts General Hospital), Amir T. Fathi(University of Southern California), Evan C. Chen(Dana-Farber Cancer Institute), Kelly Bridgham(Massachusetts General Hospital), Olga Pozdnyakova(Brigham and Women's Hospital), Mahesh Vidula(Hospital of the University of Pennsylvania), Andrew M. Brunner(Harvard University)
Leukemia Research Reports
January 1, 2018
10.1016/j.lrr.2018.05.001
Cited by 9

Related Papers

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
|Blood|2017|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2016|297